Understanding Angelman Syndrome - A Comprehensive Guide to the Genetic Disorder

Angelman Syndrome (AS) is a rare genetic disorder that primarily affects the nervous system, leading to developmental delays, intellectual disabilities, and severe speech impairments. Named after British paediatrician Dr. Harry Angelman, who first described the condition in 1965, AS is often misdiagnosed due to its overlapping symptoms with autism and cerebral palsy. With increased awareness and advancements in genetic testing, early diagnosis and intervention are now more achievable.

What Causes Angelman Syndrome?

Angelman Syndrome is typically caused by the deletion or mutation of the UBE3A gene on the maternal copy of chromosome 15. This gene plays a crucial role in brain development and function. There are four main genetic mechanisms that can lead to AS:

1. Deletion of the Maternal Chromosome 15q11-q13 Region: The most common cause, accounting for about 70% of cases.
2. UBE3A Mutation: A mutation in the UBE3A gene itself, affecting around 10% of cases.
3. Paternal Uniparental Disomy (UPD): Both copies of chromosome 15 are inherited from the father, leading to about 3–5% of cases.
4. Imprinting Defect: A defect in the imprinting process affecting the expression of the UBE3A gene.

Recognising the Symptoms of Angelman Syndrome

• Developmental Delays: Children with AS may not crawl or walk at the expected age and may have difficulty with motor skills.
• Speech Impairment: Most individuals have little to no speech, though they can communicate using nonverbal methods.
• Happy Demeanour: Individuals with AS often have a very happy, excitable demeanour with frequent smiling and laughing.
• Seizures: Epilepsy is common, with seizures usually beginning between ages 2–3 years.
• Movement and Balance Disorders: Individuals may have a jerky, puppet-like movement and struggle with balance.

Diagnosis and Genetic Testing for Angelman Syndrome

Diagnosing AS typically involves a combination of clinical evaluation and genetic testing. Key diagnostic tests include:

1. Methylation Analysis: Can detect most cases caused by a deletion or imprinting defect.
2. UBE3A Gene Sequencing: Used to detect mutations in the UBE3A gene.
3. Chromosomal Microarray Analysis (CMA): Can identify the deletion of the 15q11-q13 region.

Early diagnosis is crucial for managing the condition effectively. Once diagnosed, genetic counselling can help families understand the disorder and discuss the risks of recurrence in future pregnancies.

Treatment and Management

There is currently no cure for Angelman Syndrome, but various therapies can significantly improve quality of life:

• Speech Therapy: Helps develop alternative communication methods such as sign language or communication devices.
• Physical Therapy: Improves motor skills, balance, and coordination.
• Occupational Therapy: Focuses on improving daily living skills.
• Behavioural Therapy: Addresses hyperactivity, short attention span, and other behavioural issues.
• Medications: Anticonvulsant medications manage seizures; other medications address sleep disturbances or hyperactivity.

The Role of Genetic Testing

Genetic testing has revolutionised the way we understand and diagnose Angelman Syndrome. For families with a history of AS or those concerned about genetic disorders, genetic counselling and testing can provide clarity and peace of mind. Whole Exome Sequencing by MapmyGenome provides comprehensive genetic insights that can guide further testing and consultation for complex neurological conditions.

Conclusion

Angelman Syndrome, though rare, significantly impacts the lives of those affected and their families. Early diagnosis through genetic testing and a comprehensive treatment plan can help manage symptoms and improve quality of life.